Top Ten most popular articles on Pharmafile.com this week!
pharmafile | December 21, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AstraZeneca, Eisai, Eli Lilly, Novartis, Teva, Tilray, brexit, celltrion, pharma, top 10
Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration worth billions. Meanwhile Japanese company Taisho revealed they were set to buy Bristol-Myers Squibb’s consumer healthcare business in a deal worth $1.6 billion. To top it off Swiss pharma giant Novartis signed a deal with Canadian cannabis company which propelled the latter’s stocks up by more than 11%.
Results and approvals however filled in the gaps as Eisai, AstraZeneca, Eli Lilly, Celltrion and Teva all came out well when it came to clinical trials. Nevertheless Brexit chaos continued as Simon Dukes claimed that no-deal preparation stockpiling was putting pressure on the supply chain and causing prices to rise.
Check out this weeks’ top ten at Pharmafile.com!
10. Celltrion and Teva’s Herceptin biosimilar secures FDA approval in breast cancer
Israeli and South Korean-based drug makers Teva and Celltrion are set to move in on the market share occupied by Roche and Genentech’s Herceptin (trastuzumab) with the announcement that their own biosimilar version of the drug has received approval from the FDA.
9. China becomes first country to approve roxadustat in chronic kidney disease
AstraZeneca has announced that its partner Fibrogen has secured the first national approval for its hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat, with China becoming the first country to authorise the drug.
8. Taisho Pharma to buy Bristol-Myers Squibb’s consumer health business in deal worth $1.6 bn
Japanese company Taisho Pharmaceuticals has offered Bristol-Myers Squibb $1.6 billion for its UPSA consumer health business.
7. AstraZeneca scores hat trick in ovarian cancer and anaemia clinical trials
Anglo-Swedish multinational AstraZeneca has revealed that its ovarian cancer drug (Lynparza) and anaemia treatment (Roxadustat) have met their goals in three separate late stage trials.
6. Eli Lilly’s Taltz shows superiority over AbbVie’s Humira
A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naïve when compared to AbbVie’s Humira.
5. NICE recommends Lenvima as alternative first-line therapy for advanced liver cancer
UK drug watchdog NICE has revealed that it has recommended Eisai’s Lenvima (lenvatinib) for use on the NHS in England and Wales as a life-extending intervention for patients with advanced liver cancer whose liver is well-functioning but whose disease cannot be treated surgically.
4. No-deal Brexit stockpiling puts pressure on supply chain
The stockpiling of medicines in preparation for a no-deal Brexit is putting pressure on the supply chain and causing shortages of generic medicines, according to Simon Dukes, chief executive of the PSNC. The increased demand has in turn led to fluctuating prices, additional costs that will have to be picked up by the NHS.
3. Novartis withdraw marketing application for heart drug
Swiss multinational Novartis has withdrawn a European Medicines Agency (EMA) marketing application for canakinumab for the prevention of serious events such as stroke, myocardial infarction (MI) or death in patients who have had an MI.
2. Novartis inks deal with Canadian cannabis firm Tilray
Shares in Canadian cannabis company Tilray jumped by more than 11% today after the British Columbia-based firm announced its entry into a global supply and distribution agreement with Swiss multinational Novartis.
1. GSK and Pfizer combine healthcare units in multibillion dollar deal
American multinational Pfizer and British firm GlaxoSmithKline are set to combine their consumer healthcare units in a venture worth billions.
Related Content
AstraZeneca’s Trixeo approved in EU for asthma
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
